In Alzheimer's disease (AD), Aβ deposits form slowly, several decades before further
pathological events trigger neurodegeneration and dementia. However, a substantial …

Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for
various cerebral proteopathies. Here we leverage the unique characteristics of the …

Summary Background Models of Alzheimer's disease propose a sequence of amyloid β (Aβ)
accumulation, hypometabolism, and structural decline that precedes the onset of clinical …

Almost all Alzheimer's disease (AD) therapeutic trials have failed in recent years. One of the
main reasons for failure is due to designing the disease-modifying clinical trials at the …

Tauopathy is a hallmark pathology of Alzheimer's disease with a strong relationship with
cognitive impairment. As such, understanding tau may be a key to clinical interventions. In …

Both healthy and pathological brain aging are characterized by various degrees of cognitive
decline that strongly correlate with morphological changes referred to as cerebral atrophy …

Portable, low-field magnetic resonance imaging (LF-MRI) of the brain may facilitate point-of-
care assessment of patients with Alzheimer's disease (AD) in settings where conventional …

Develo** and validating sensitive biomarkers for the presymptomatic stage of familial
frontotemporal dementia is an important step in early diagnosis and for the design of future …

In genetic frontotemporal dementia, cross-sectional studies have identified profiles of
presymptomatic neuroanatomical loss for C9orf72 repeat expansion, MAPT, and GRN …

INTRODUCTION A biphasic model for brain structural changes in preclinical Alzheimer's
disease (AD) could reconcile some conflicting and paradoxical findings in observational …